MX2019011544A - Inhibidores novedosos. - Google Patents
Inhibidores novedosos.Info
- Publication number
- MX2019011544A MX2019011544A MX2019011544A MX2019011544A MX2019011544A MX 2019011544 A MX2019011544 A MX 2019011544A MX 2019011544 A MX2019011544 A MX 2019011544A MX 2019011544 A MX2019011544 A MX 2019011544A MX 2019011544 A MX2019011544 A MX 2019011544A
- Authority
- MX
- Mexico
- Prior art keywords
- heteroaryl
- heterocyclyl
- cycloalkyl
- aryl
- amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1705263.0A GB201705263D0 (en) | 2017-03-31 | 2017-03-31 | Novel inhibitors |
| PCT/EP2018/058391 WO2018178384A1 (en) | 2017-03-31 | 2018-04-03 | Novel inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019011544A true MX2019011544A (es) | 2019-12-16 |
Family
ID=58682483
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019011544A MX2019011544A (es) | 2017-03-31 | 2018-04-03 | Inhibidores novedosos. |
| MX2022007317A MX2022007317A (es) | 2017-03-31 | 2019-09-26 | Inhibidores novedosos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007317A MX2022007317A (es) | 2017-03-31 | 2019-09-26 | Inhibidores novedosos. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11339152B2 (https=) |
| EP (1) | EP3601269A1 (https=) |
| JP (3) | JP7674811B2 (https=) |
| KR (2) | KR20250002689A (https=) |
| CN (2) | CN110719910B (https=) |
| AU (2) | AU2018246382C1 (https=) |
| CA (2) | CA3221839A1 (https=) |
| EA (1) | EA201992120A1 (https=) |
| GB (1) | GB201705263D0 (https=) |
| IL (3) | IL297534A (https=) |
| MX (2) | MX2019011544A (https=) |
| WO (1) | WO2018178384A1 (https=) |
| ZA (1) | ZA201905811B (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2536650A (en) | 2015-03-24 | 2016-09-28 | Augmedics Ltd | Method and system for combining video-based and optic-based augmented reality in a near eye display |
| US12521201B2 (en) | 2017-12-07 | 2026-01-13 | Augmedics Ltd. | Spinous process clamp |
| US12458411B2 (en) | 2017-12-07 | 2025-11-04 | Augmedics Ltd. | Spinous process clamp |
| EP3787543A4 (en) | 2018-05-02 | 2022-01-19 | Augmedics Ltd. | REGISTRATION OF A FIDUCIAL MARKER FOR AN AUGMENTED REALITY SYSTEM |
| CR20210163A (es) * | 2018-10-05 | 2021-06-24 | Pfizer | Inhibidores de pde4 que contienen boro |
| US11766296B2 (en) | 2018-11-26 | 2023-09-26 | Augmedics Ltd. | Tracking system for image-guided surgery |
| WO2020142764A1 (en) * | 2019-01-06 | 2020-07-09 | Psomagen Inc. | Htra inhibitors and caga inhibitors and use thereof |
| US11980506B2 (en) | 2019-07-29 | 2024-05-14 | Augmedics Ltd. | Fiducial marker |
| US12178666B2 (en) | 2019-07-29 | 2024-12-31 | Augmedics Ltd. | Fiducial marker |
| US11382712B2 (en) | 2019-12-22 | 2022-07-12 | Augmedics Ltd. | Mirroring in image guided surgery |
| AU2021208943B2 (en) | 2020-01-17 | 2023-10-05 | Daegu-Gyeongbuk Medical Innovation Foundation | Novel compound, preparation method thereof, and use thereof |
| KR102433502B1 (ko) * | 2020-01-17 | 2022-08-18 | 재단법인 대구경북첨단의료산업진흥재단 | 신규 화합물, 이의 제조방법 및 이의 용도 |
| US11389252B2 (en) | 2020-06-15 | 2022-07-19 | Augmedics Ltd. | Rotating marker for image guided surgery |
| US12502163B2 (en) | 2020-09-09 | 2025-12-23 | Augmedics Ltd. | Universal tool adapter for image-guided surgery |
| US12239385B2 (en) | 2020-09-09 | 2025-03-04 | Augmedics Ltd. | Universal tool adapter |
| WO2022086920A1 (en) * | 2020-10-20 | 2022-04-28 | Blacksmith Medicines, Inc. | Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof |
| AR124297A1 (es) * | 2020-12-10 | 2023-03-15 | Bayer Ag | Ácidos pirazol piperidin carboxílicos sustituidos |
| US11896445B2 (en) | 2021-07-07 | 2024-02-13 | Augmedics Ltd. | Iliac pin and adapter |
| US12150821B2 (en) | 2021-07-29 | 2024-11-26 | Augmedics Ltd. | Rotating marker and adapter for image-guided surgery |
| US12475662B2 (en) | 2021-08-18 | 2025-11-18 | Augmedics Ltd. | Stereoscopic display and digital loupe for augmented-reality near-eye display |
| CN117567435A (zh) * | 2022-01-30 | 2024-02-20 | 上海市第十人民医院 | 谷氨酰胺环化酶抑制剂及其应用 |
| WO2023205173A1 (en) * | 2022-04-20 | 2023-10-26 | Blacksmith Medicines, Inc. | Substituted piperidines and substituted tetrahydropyridines as immune-modulating compounds |
| WO2023203521A1 (en) | 2022-04-21 | 2023-10-26 | Augmedics Ltd. | Systems and methods for medical image visualization |
| CN114560817B (zh) * | 2022-04-25 | 2022-10-25 | 北京大学第三医院（北京大学第三临床医学院） | 一种用于抑制纤维化的小分子药物及其应用 |
| AR130003A1 (es) | 2022-08-03 | 2024-10-23 | Boehringer Ingelheim Int | Derivados de piperidinilpiridinilcarbonitrilo como inhibidores de glutaminil-péptido ciclotransferasa y proteína tipo glutaminil-péptido ciclotransferasa |
| JP2025531829A (ja) | 2022-09-13 | 2025-09-25 | オーグメディックス リミテッド | 画像誘導医療介入のための拡張現実アイウェア |
| CN120379972A (zh) * | 2022-12-20 | 2025-07-25 | 深圳湾实验室 | 一种靶向usp1的小分子抑制剂及其应用 |
| KR20250121039A (ko) | 2022-12-22 | 2025-08-11 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루타미닐-펩타이드 사이클로트랜스퍼라제 및 글루타미닐-펩타이드 사이클로트랜스퍼라제 유사 단백질의 억제제로서 페닐피페리딘 유도체 |
| CR20250377A (es) | 2023-03-13 | 2025-11-19 | Boehringer Ingelheim Int | Derivados de fenilpiperidina como inhibidores de la glutaminil-péptido ciclotransferasa y proteína similar a glutaminil-péptido ciclotransferasa |
| IL326207A (en) | 2023-08-04 | 2026-03-01 | Boehringer Ingelheim Int | History of piperidinylpyridinylcarbonitrile as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase-like protein |
| US20250059166A1 (en) | 2023-08-04 | 2025-02-20 | Boehringer Ingelheim International Gmbh | Piperidinylpyridinylcarbonitrile derivatives as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase like protein |
| IL326386A (en) | 2023-08-14 | 2026-04-01 | Boehringer Ingelheim Int | History of piperidinylpyridinylcarbonitrile as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase-like protein |
| CN117538462B (zh) * | 2024-01-10 | 2024-03-26 | 地奥集团成都药业股份有限公司 | 一种氨氯地平贝那普利胶囊有关物质的检测方法 |
| WO2025240620A1 (en) * | 2024-05-14 | 2025-11-20 | Pronovo Therapeutics Inc. | Selective dual agonists of muscarinic 1 and 4 receptors and therapeutic uses thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0640599T3 (da) * | 1993-08-26 | 1998-09-28 | Ono Pharmaceutical Co | 4-Aminopyrimidin-derivater |
| US6262059B1 (en) | 1995-06-07 | 2001-07-17 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with quinazoline derivatives |
| US7064215B2 (en) * | 2001-07-03 | 2006-06-20 | Chiron Corporation | Indazole benzimidazole compounds |
| US7642278B2 (en) * | 2001-07-03 | 2010-01-05 | Novartis Vaccines And Diagnostics, Inc. | Indazole benzimidazole compounds |
| US8673924B2 (en) * | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| WO2005004818A2 (en) * | 2003-07-09 | 2005-01-20 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
| EP1781659B1 (en) * | 2003-07-16 | 2008-11-05 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| AU2005205201B2 (en) * | 2004-01-12 | 2011-05-12 | Merck Serono Sa | Thiazole derivatives and use thereof |
| EP1718306A2 (en) * | 2004-02-20 | 2006-11-08 | Chiron Corporation | Modulation of inflammatory and metastatic processes |
| MX2007000631A (es) * | 2004-07-16 | 2007-03-30 | Sunesis Pharmaceuticals Inc | Tienopirimidinas utiles como inhibidores de aurora cinasa. |
| JP2008508358A (ja) * | 2004-08-02 | 2008-03-21 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物 |
| GB0520958D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| WO2007067537A1 (en) * | 2005-12-07 | 2007-06-14 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine kinase inhibiting compounds |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| AR060358A1 (es) * | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
| US7893058B2 (en) * | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| CN101511800B (zh) * | 2006-07-14 | 2013-02-27 | 坎莫森特里克斯公司 | 三唑基苯基苯磺酰胺 |
| JP2010514693A (ja) * | 2006-12-22 | 2010-05-06 | ノバルティス アーゲー | Ｐｄｋ１阻害のためのキナゾリン |
| CN101568529A (zh) * | 2006-12-22 | 2009-10-28 | 诺瓦提斯公司 | 作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物 |
| WO2008128986A1 (en) * | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Urea derivatives as glutaminyl cyclase inhibitors |
| WO2008128984A1 (en) * | 2007-04-20 | 2008-10-30 | Probiodrug Ag | Aminopyrimidine derivatives as glutaminyl cyclase inhibitors |
| JP5611826B2 (ja) * | 2007-09-04 | 2014-10-22 | ザ スクリプス リサーチ インスティテュート | タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン |
| EP2326627A1 (en) * | 2008-08-20 | 2011-06-01 | Schering Corporation | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| CN102186475B (zh) * | 2008-09-04 | 2016-08-03 | 前体生物药物股份公司 | 新抑制剂 |
| JP5934645B2 (ja) * | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| JP6026284B2 (ja) * | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) * | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| WO2011131748A2 (en) * | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| JP2014500254A (ja) * | 2010-11-09 | 2014-01-09 | セルゾーム リミティッド | Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体 |
| NO2638031T3 (https=) * | 2010-11-10 | 2018-03-10 | ||
| US8785459B2 (en) | 2011-12-27 | 2014-07-22 | Development Center For Biotechnology | Quinazoline compounds as kinase inhibitors |
| EP2844652B1 (en) * | 2012-05-03 | 2019-03-13 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| WO2014081718A1 (en) * | 2012-11-20 | 2014-05-30 | Genentech, Inc. | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| MX367855B (es) * | 2013-03-15 | 2019-09-09 | Probiodrug Ag | Inhibidores novedosos. |
| MA40957A (fr) * | 2014-10-09 | 2017-09-19 | Biomarin Pharm Inc | Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies |
| CA2979302A1 (en) * | 2015-05-13 | 2016-11-17 | Selvita S.A. | Substituted quinoxaline derivatives |
| EP3334733A1 (en) * | 2015-08-10 | 2018-06-20 | Pfizer Inc | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| SG11201804901WA (en) * | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| US10034861B2 (en) * | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
-
2017
- 2017-03-31 GB GBGB1705263.0A patent/GB201705263D0/en not_active Ceased
-
2018
- 2018-04-03 CA CA3221839A patent/CA3221839A1/en active Pending
- 2018-04-03 IL IL297534A patent/IL297534A/en unknown
- 2018-04-03 CN CN201880035826.8A patent/CN110719910B/zh active Active
- 2018-04-03 IL IL269196A patent/IL269196B2/en unknown
- 2018-04-03 EP EP18718725.7A patent/EP3601269A1/en active Pending
- 2018-04-03 US US16/497,040 patent/US11339152B2/en active Active
- 2018-04-03 AU AU2018246382A patent/AU2018246382C1/en active Active
- 2018-04-03 CA CA3057783A patent/CA3057783A1/en active Pending
- 2018-04-03 WO PCT/EP2018/058391 patent/WO2018178384A1/en not_active Ceased
- 2018-04-03 KR KR1020247039667A patent/KR20250002689A/ko active Pending
- 2018-04-03 MX MX2019011544A patent/MX2019011544A/es unknown
- 2018-04-03 KR KR1020197028930A patent/KR102737532B1/ko active Active
- 2018-04-03 JP JP2019553478A patent/JP7674811B2/ja active Active
- 2018-04-03 CN CN202310828597.8A patent/CN117024352A/zh active Pending
- 2018-04-03 EA EA201992120A patent/EA201992120A1/ru unknown
-
2019
- 2019-09-03 ZA ZA2019/05811A patent/ZA201905811B/en unknown
- 2019-09-26 MX MX2022007317A patent/MX2022007317A/es unknown
-
2022
- 2022-05-05 US US17/737,602 patent/US12384772B2/en active Active
- 2022-05-20 JP JP2022082769A patent/JP7589191B2/ja active Active
- 2022-10-05 AU AU2022246405A patent/AU2022246405B2/en active Active
-
2023
- 2023-10-22 IL IL307911A patent/IL307911B1/en unknown
-
2024
- 2024-07-03 JP JP2024107135A patent/JP2024153639A/ja active Pending
-
2025
- 2025-07-07 US US19/261,178 patent/US20260001873A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019011544A (es) | Inhibidores novedosos. | |
| AR115949A1 (es) | Compuestos heterocíclicos | |
| UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
| PE20231935A1 (es) | Moduladores de la via de estres integrada | |
| MX383363B (es) | Compuestos macrociclicos como inhibidores de cinasas asociadas al receptor de interleucina1/4 (irak1/4) y usos de los mismos. | |
| PE20221339A1 (es) | Inhibidores de parp1 | |
| EA202091893A1 (ru) | Новые кристаллические формы | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| NZ712352A (en) | Novel inhibitors of glutaminyl cyclase | |
| MX2017009624A (es) | Macrociclos de piridazinona como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
| EA201992884A2 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| NO341631B1 (no) | Hydroksybenzamidderivater og deres anvendelse, fremgangsmåte for fremstilling og farmasøytiske sammensetninger | |
| MX378499B (es) | Compuestos antifungicos. | |
| WO2015200677A3 (en) | Prmt5 inhibitors and uses thereof | |
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| MX2021002199A (es) | Inhibidores de sarcomeros cardiacos. | |
| MY209034A (en) | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors | |
| BR112018011788A2 (pt) | formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação | |
| MX375153B (es) | Compuestos antihelminticos. | |
| BR112021018692A2 (pt) | 1,1-dióxido de isotiazolidina e 1,4-butanossultona contendo derivados de rapamicina e usos dos mesmos | |
| PY1865684A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| AR101197A1 (es) | Pirimidinas 2,5-sustituidas | |
| BR112016023299A8 (pt) | composto tricíclico e inibidor de jak, agente preventivo, terapêutico ou de melhoria para doenças contra as quais inibição de jak é eficaz e para artrite reumatoide, medicamento e utilização desses compostos | |
| EA202090642A1 (ru) | Ингибиторы глутаминилциклазы |